In a 29-year-old female with shortness of breath and a narrow‑complex tachycardia on ECG who is hemodynamically stable (normotensive, normal respiratory rate, normothermic, oxygen saturation 95% on room air), what is the first‑line medication?

Adenosine

For this hemodynamically stable 29-year-old woman with narrow-complex tachycardia, adenosine is the first-line medication of choice. 1, 2

Clinical Reasoning

This patient presents with:

• Hemodynamic stability: BP 110/70, normal mental status, adequate oxygenation (95% on room air)
• Narrow-complex tachycardia (based on the clinical scenario description)
• Symptomatic (shortness of breath) but not unstable

The 2025 AHA Guidelines 1 and 2015 ACC/AHA/HRS Guidelines 2 establish a clear treatment hierarchy for stable narrow-complex tachycardias:

Treatment Algorithm for Stable Narrow-Complex Tachycardia

1. First attempt vagal maneuvers (if time permits and patient cooperative)

   • Modified Valsalva with passive leg raise
   • Carotid massage (after confirming no bruit)
   • Ice to face

2. If vagal maneuvers fail or not feasible → Adenosine

   • Dosing: 6 mg rapid IV push followed by 20 mL saline flush
   • If no response after 1-2 minutes: 12 mg rapid IV push
   • Can repeat 12 mg dose once more if needed

3. If adenosine fails → Consider calcium channel blockers or beta-blockers

4. If medications fail → Synchronized cardioversion

Why Adenosine is First-Line

Adenosine demonstrates 78-96% success rates for terminating supraventricular tachycardias (AVNRT/AVRT) 2. The drug:

• Has an extremely short half-life (seconds), making side effects transient
• Blocks AV node conduction, terminating most reentrant SVTs
• Serves dual diagnostic and therapeutic purposes—if it doesn't terminate the rhythm, it may unmask underlying atrial activity (flutter, fibrillation, or atrial tachycardia) 1

Why NOT the Other Options

Amiodarone: Reserved for refractory cases or specific indications (pre-excited atrial fibrillation, wide-complex tachycardias). Not first-line for stable narrow-complex tachycardia 1, 3. The 2019 ESC guidelines actually downgraded amiodarone for acute narrow-complex SVT management 4.

Epinephrine: Absolutely contraindicated—would worsen tachycardia and potentially destabilize the patient.

Cardioversion: Reserved for hemodynamically unstable patients (systolic BP <80 mmHg, altered mental status, signs of shock, acute heart failure, chest pain) 1, 2. This patient is stable, so pharmacologic therapy should be attempted first.

Critical Caveats

• Contraindicated in asthma due to bronchospasm risk 1, 3
• Have a defibrillator immediately available—adenosine may precipitate atrial fibrillation, which can conduct rapidly in patients with accessory pathways (WPW) 3
• Administer via proximal IV as rapid bolus for maximum efficacy 2
• Reduce dose to 1 mg in post-cardiac transplant patients or those on dipyridamole/carbamazepine 3
• Common transient side effects: flushing, chest discomfort, sense of impending doom (last <60 seconds) 2, 5

If Adenosine Fails

The next tier includes IV diltiazem, verapamil, or beta-blockers (all Class IIa recommendations) 1, 2, 6. However, these agents:

• Must be given slowly to avoid hypotension
• Are contraindicated if there's any suspicion of ventricular tachycardia or pre-excited atrial fibrillation
• Should be avoided in suspected heart failure (especially calcium channel blockers)